Blueprint Medicines (BPMC) Stock Price, News & Analysis

Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $99.95 to $102.52
• 50-Day Range: $79.22 to $104.64
• 52-Week Range: $73.04 to $121.90
• Volume: 709,926 shs
• Average Volume: 781,125 shs
• Market Capitalization: $6.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $126.56
• Consensus Rating: Moderate Buy

Blueprint Medicines Stock Analysis - MarketRank™

Blueprint Medicines scored higher than 51% of companies evaluated by MarketBeat, and ranked 724th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Blueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Blueprint Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Blueprint Medicines is -92.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Blueprint Medicines is -92.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Blueprint Medicines has a P/B Ratio of 21.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.76% of the outstanding shares of Blueprint Medicines have been sold short.

Short Interest Ratio / Days to Cover

Blueprint Medicines has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Blueprint Medicines has recently increased by 1.80%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Blueprint Medicines does not currently pay a dividend.

Dividend Growth

Blueprint Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.76% of the outstanding shares of Blueprint Medicines have been sold short.

Short Interest Ratio / Days to Cover

Blueprint Medicines has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Blueprint Medicines has recently increased by 1.80%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.29

News Sentiment

Blueprint Medicines has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Blueprint Medicines this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,256,490.00 in company stock.

Percentage Held by Insiders

Only 4.21% of the stock of Blueprint Medicines is held by insiders.

BPMC Stock Analysis - Frequently Asked Questions

How have BPMC shares performed this year?

Blueprint Medicines' stock was trading at $87.22 on January 1st, 2025. Since then, BPMC stock has increased by 14.7% and is now trading at $100.06.
View the best growth stocks for 2025 here.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.32. The business's revenue was up 55.5% compared to the same quarter last year.
Read the conference call transcript.

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' top institutional investors include Vanguard Group Inc. (10.28%), Price T Rowe Associates Inc. MD (8.39%), Wellington Management Group LLP (4.76%) and T. Rowe Price Investment Management Inc. (2.02%). Insiders that own company stock include Jeffrey W Albers, Kate Haviland, Fouad Namouni, Christina Rossi, Tracey L Mccain, Michael Landsittel, Debra Durso-Bumpus, Percy H Carter, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley.
View institutional ownership trends.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPMC
• CIK: 1597264
• Web: www.blueprintmedicines.com
• Phone: (617) 374-7580
• Fax: N/A
• Employees: 640
• Year Founded: 2011

Price Target and Rating

• Average Stock Price Target: $126.56
• High Stock Price Target: $151.00
• Low Stock Price Target: $88.00
• Potential Upside/Downside: +26.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.09 million
• Net Margins: -13.19%
• Pretax Margin: -12.94%
• Return on Equity: -77.49%
• Return on Assets: -20.84%

Debt

• Debt-to-Equity Ratio: 1.15
• Current Ratio: 2.85
• Quick Ratio: 2.80

Sales & Book Value

• Annual Sales: $562.12 million
• Price / Sales: 11.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.67 per share
• Price / Book: 21.43

Miscellaneous

• Outstanding Shares: 64,582,000
• Free Float: 61,216,000
• Market Cap: $6.46 billion
• Optionable: Optionable
• Beta: 0.83